We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+3.85%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$28.3M
Cap. Flow
+$26.6M
Cap. Flow %
0.86%
Top 10 Hldgs %
33.83%
Holding
206
New
17
Increased
43
Reduced
39
Closed
34

Top Buys

Rank Stock Value
1
RLYB icon
Rallybio
RLYB
+$33.8M
2
IDXX icon
Idexx Laboratories
IDXX
+$30.1M
3
GH icon
Guardant Health
GH
+$27.2M
4
AMGN icon
Amgen
AMGN
+$25.7M
5
AZN icon
AstraZeneca
AZN
+$21.2M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$35.4M
2
RMD icon
ResMed
RMD
+$33.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.9M
4
DXCM icon
DexCom
DXCM
+$20.1M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.51%
2 Real Estate 2.72%
3 Industrials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCK icon
26
McKesson
MCK
$101B
$36.2M 1.17%
181,577
+30,862
+20% +$6.17M
ALNY icon
27
Alnylam Pharmaceuticals
ALNY
$27.5B
$35.8M 1.15%
189,695
+55,200
+41% +$10.4M
SGEN
28
DELISTED
Seagen Inc. Common Stock
SGEN
$35.2M 1.13%
207,334
-3,425
-2% -$533K
ZBH icon
29
Zimmer Biomet
ZBH
$18.4B
$32.6M 1.05%
229,384
– –
CRL icon
30
Charles River Laboratories
CRL
$11.3B
$32.4M 1.04%
78,484
+23,810
+44% +$9.89M
NVAX icon
31
Novavax
NVAX
$1.22B
$31.4M 1.01%
151,491
+63,895
+73% +$14.1M
ZTS icon
32
Zoetis
ZTS
$31.9B
$27.7M 0.89%
142,597
+86,076
+152% +$17.4M
HCA icon
33
HCA Healthcare
HCA
$85.7B
$27.2M 0.88%
111,961
-12,782
-10% -$3.12M
UTHR icon
34
United Therapeutics
UTHR
$26.2B
$26.8M 0.86%
144,940
+5,502
+4% +$1.08M
LH icon
35
Labcorp
LH
$25.9B
$26.6M 0.86%
110,180
+28,265
+35% +$7.12M
ICLR icon
36
Icon
ICLR
$12.8B
$25.9M 0.83%
98,871
+62,514
+172% +$15.2M
DXCM icon
37
DexCom
DXCM
$28.8B
$23.5M 0.76%
171,920
-159,100
-48% -$20.1M
ONC
38
BeOne Medicines Ltd
ONC
$33.4B
$23.1M 0.75%
63,772
+17,789
+39% +$5.82M
MOH icon
39
Molina Healthcare
MOH
$10.2B
$22.7M 0.73%
83,625
+20,015
+31% +$5.29M
BNTX icon
40
BioNTech
BNTX
$23.5B
$22M 0.71%
80,757
+23,684
+41% +$7.53M
EW icon
41
Edwards Lifesciences
EW
$50B
$22M 0.71%
194,630
-26,925
-12% -$3.07M
EXAS
42
DELISTED
Exact Sciences
EXAS
$21.5M 0.69%
225,282
+25,628
+13% +$2.71M
XRAY icon
43
Dentsply Sirona
XRAY
$2.75B
$21.3M 0.69%
367,521
-14,823
-4% -$914K
SYNH
44
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$21.3M 0.69%
243,633
– –
HUM icon
45
Humana
HUM
$44B
$20.7M 0.67%
53,135
-5,000
-9% -$2.12M
ISRG icon
46
Intuitive Surgical
ISRG
$126B
$19.9M 0.64%
60,006
-3,882
-6% -$1.3M
PFE icon
47
Pfizer
PFE
$142B
$19.4M 0.62%
450,379
– –
CTLT
48
DELISTED
CATALENT, INC.
CTLT
$19.2M 0.62%
143,913
+63,888
+80% +$7.98M
IQV icon
49
IQVIA
IQV
$39.1B
$18.4M 0.59%
76,644
+19,878
+35% +$5.02M
CRSP icon
50
CRISPR Therapeutics
CRSP
$4.77B
$18.2M 0.59%
162,337
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Tekla Capital Management held 206 positions worth $3.11B, up 0.92% from $3.08B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Tekla Capital Management's Q3 2021 filing shows 17 new, 43 increased, 39 reduced and 34 closed positions. Its largest new stake was Rallybio: 288,584 shares worth $37.6M. The largest sale was Elevance Health, an estimated $35.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q3 2021 buy was Rallybio: 288,584 shares worth $37.6M.
  • Tekla Capital Management added most to Idexx Laboratories in Q3 2021, an estimated $30.1M increase.
  • Tekla Capital Management's biggest Q3 2021 reduction was Elevance Health, cutting an estimated $35.4M.
  • Tekla Capital Management fully exited Iovance Biotherapeutics in Q3 2021, selling an estimated $12.2M.
  • Tekla Capital Management's ten largest holdings make up 34% of its $3.11B portfolio in Q3 2021.
  • Tekla Capital Management opened 17 new positions and closed 34 in Q3 2021.
  • Tekla Capital Management's portfolio value rose 0.92% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.